SCHEMBL5618973

SCHEMBL5618973

CNc1nccn2c(-c3cccc(NC(=O)CNCc4ccccc4)c3)cnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTK P33981 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ BRAF P15056 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ FGFR3 P22607 4/20 0.40
▸ KDR P35968 3/20 0.40
▸ HDAC3 O15379 2/20 0.40
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC2 Q92769 2/20 0.40
▸ HDAC10 Q969S8 2/20 0.40
▸ HDAC8 Q9BY41 2/20 0.40
▸ HDAC6 Q9UBN7 2/20 0.40
▸ NPY5R Q15761 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ FLT3 P36888 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ IKBKB O14920 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5664283 0.91 TTK (0.49) TTKALDH1A1MAPTKDM4EGAA
SCHEMBL5618691 0.90 TTK (0.53) TTKALDH1A1MAPTKDM4EGAA
SCHEMBL5416134 0.82 FYN (0.54) TTKBRAFFLT3
SCHEMBL5618376 0.81 JAK3 (0.51) TTKALDH1A1BRAFKDRRECQL
SCHEMBL5618489 0.79 EGFR (0.46) TTKALDH1A1BRAFFGFR3KDR
SCHEMBL14573282 0.79 FGFR3 (0.43) TTKBRAFFGFR3KDRFLT3
SCHEMBL5618369 0.79 JAK3 (0.54) ALDH1A1FLT3
SCHEMBL5618277 0.78 JAK3 (0.45) TTKBRAFFGFR3KDR
SCHEMBL5618971 0.78 TTK (0.50) TTKALDH1A1KDM4EFLT3
SCHEMBL3466056 0.77 TTK (0.57) TTKBRAFTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 TTK 69/4885ALDH1A1 2826/4885MAPT 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback